ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with HER2-Expression – UroToday

Written by

admin

in

  1. ESMO 2025: Disitamab Vedotin plus Toripalimab Versus Chemotherapy in First-Line Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) with HER2-Expression  UroToday
  2. Loqtorzi Extends Survival in HER2-Positive Advanced Urothelial Cancer  CUREtoday.com
  3. Disitamab Vedotin/Toripalimab Combo Prolongs Survival in Frontline HER2+ Urothelial Cancer  CancerNetwork
  4. RC48-C016: DV + Toripalimab Boosts Survival in HER2+ UC  Oncodaily

Continue Reading

More posts